TARGETING MICROBIAL BIOFILMS ALTERING CHRONIC WOUND HEALING: NEW BREAKTHROUGH IN DRUG DEVELOPMENT USING SILVER

Abstract

Biofilm development is a potent inducer for many microorganisms that inflict chronic infections. Conventional antimicrobials face significant hurdles in dealing with biofilms and drug resistance because of the multi-factor nature of these processes. Despite this, bacterial biofilms remain a mystery, and their management methods are still lacking. Biofilms may lead to persistent illness and need surgical excision of affected regions if standard antimicrobial treatments fail to eliminate them. One of the most significant concerns in antibacterial medication research is discovering effective treatments for biofilm infections. Recent wound biofilm infection therapy research focuses on nanotechnology-based medication delivery systems and combination therapies. Biofilm-targeting medications are still in the early stages of research, although several promising techniques are already being tested. Current understanding of biofilm physiology and pathology is reviewed and discussed here, as is how a thorough understanding of biofilm physical and biological properties might influence treatment techniques and molecular targets for the creation of anti-biofilm medications. Specifically, we are interested in treatment approaches targeting the extracellular matrix, dormant cells, additional crucial microbial biofilm structure, functional features, and drug tolerance mechanisms. In many clinical investigations, silver has been found to improve the healing of chronic, non-healing wounds, including silver nanoparticles. The purpose of this review is to provide an overview of recent developments in silver nanoparticle-based biofilm therapeutics and to understand the current development path.